This is the authors' abstract. We don't add key points for this paper.
Sirs, Improvement of liver function and portal hypertension have recently been described in two real-life cohorts of patients with hepatitis C virus (HCV)-induced liver cirrhosis after successful interferon-free anti-viral treatment regimens. One study investigated hepatic venous pressure gradient (HVPG), the other restoration of liver function measured by albumin, bilirubin, cholinesterase and prothrombin time.1, 2 Both studies excluded patients with hepatocellular carcinoma (HCC). HVPG measurement is often not feasible in clinical routine and improvement of single laboratory parameters may be difficult to correlate with clinical end points, non-invasive assessment of hepatic fibrosis by transient elastography (TE) is easily applicable and correlates with portal hypertension and survival.3-5 We, therefore, provide results of TE prior to and 12 weeks after interferon-free anti-viral therapies of HCV-induced advanced fibrosis and cirrhosis with and without HCC. Patients with HCV-induced advanced fibrosis (n = 2) and cirrhosis (n = 12) were treated with sofosbuvir/daclatasvir ± ribavirin (n = 12), sofosbuvir/simeprevir (n = 1) or sofosbuvir/ledipasvir (n = 1) for 12–24 weeks and prospectively investigated by M-probe TE including controlled attenuation parameter (CAP) (Fibroscan, Echosens, France; valid results according to Boursier et al.6). In HCC patients, the measurement site (right liver lobe) was not affected by the tumour. A CAP-value ≥252 dB/m indicated significant steatosis.7 Baseline characteristics were: 64% male, median age 58 (44–78) years, median BMI 23 (19–36) kg/m2, HCV-genotype 1/4 93%/7%, advanced fibrosis/Child A/B 14%/79%/7%, HCC treated with local ablative therapy 29%. Sustained virologic response (SVR-12) was achieved by 13/14 (93%) individuals and accompanied by improvement of INR, bilirubin and albumin levels both in cases with and without HCC. One patient with HCC relapsed after liver transplantation which was performed in the follow-up period. Median liver stiffness was 32 (10–75) kPa at baseline and 20 (5–75) kPa at follow-up (P = 0.012), median CAP 217 (100–337) dB/m and 220 (192–307) dB/m (P = 0.685) respectively. In the individual data analysis, TE improved in 11/13 cases, one patient remained stable at 75 kPa, and one individual increased from 19 to 32 kPa. Notably, in contrast to patients without HCC, individuals with HCC did not achieve a decline of liver stiffness (P = 0.034, Figure 1). Controlled attenuation parameter-values ≥252 dB/m were observed in five patients at baseline. At follow-up, three showed a CAP decrease from 337 to 307 dB/m, 301 to 236 dB/m and 252 to 213 dB/m, respectively, one case remained stable (260 and 268 dB/m), and one individual increased from 252 to 279 dB/m. In conclusion, TE correlates with recompensation of HCV induced liver cirrhosis after SVR induced by interferon-free anti-viral regimens. However, TE results >25 kPa are associated with a 45.5 higher HCC risk compared to cases with TE <10 kPa.8 Thus, although laboratory liver function parameters improved, it remains an intriguing question whether the absence of declining TE values in cirrhotic patients with HCC indicates that interferon-free anti-viral therapies might not lower the risk for HCC re-appearance. These patients may therefore require an even more intense surveillance than cirrhotic individuals who have achieved SVR and declining TE results. Declaration of personal interests: Thomas Karlas has served as a speaker for Siemens Healthcare, and has received research funding and travel grants from Echosens. Thomas Berg has served as a speaker, a consultant and an advisory board member for AbbVie, BMS, Boehringer, Gilead, Janssen, Merck, Novartis,Roche and Vertex Pharmaceuticals Incorporated, and has received research funding from Abbvie, Boehringer, Gilead, Janssen, Novartis and Roche. Johannes Wiegand has served as a speaker, a consultant and an advisory board member for AbbVie, BMS, Gilead, Roche, Siemens and Janssen, and has received research funding from Siemens. Julia Benckert, Sebastian Beer and Volker Keim have nothing to disclose. Declaration of funding interests: None.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Karlas et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: